1. Proof-of-Concept Phase 2a Trial of VH4524184 (VH-184), an Emerging Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile
Autores: Rogg L, Nuñez SA, Mingrone MV, Domingo P, Rolle CP, Güerri-Fernandez R, Estrada V, Lopez M, Hanan N, Ghita GL, Jeffrey JL, Underwood M, Castillo-Mancilla JR, Halliday F, Ezeadi E, Gartland M.
Revista: Clinical Infectious Diseases. 2026 Jun 12:ciag357. Epub ahead of print. DOI: 10.1093/cid/ciag357. PMID: 42283218.

Link: Ver abstract / página de la revista

2. Overcoming barriers, driving progress: Clinical science at IAS 2025
Autores: Cordova E, Sokhela S, Alagaratnam J, Ambrosioni J.
Revista: Journal of the International AIDS Society. 2026 Mar;29(3):e70088. DOI: 10.1002/jia2.70088. PMID: 41867101.
Link: Ver abstract / página de la revista

3. Efficacy of dolutegravir plus lamivudine in treatment-naïve people with HIV with baseline transmitted drug-resistance mutations
Autores: Cordova E, Hernandez Rendon J, Arevalo Calderon G, Seleme S, Mingrone V, Porteiro N.
Revista: AIDS. 2026 Jun 1;40(6):781-786. Epub 2026 Jan 14. DOI: 10.1097/QAD.0000000000004444. PMID: 41537536.
Link: Ver abstract / página de la revista

12. Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing available (D2ARLING): 48-week results of a phase 4, randomised, open-label, non-inferiority trial
Autores: Cordova E, Hernandez Rendon J, Mingrone V, Martin P, Arevalo Calderon G, Seleme S, Ballivian J, Porteiro N.
Revista: The Lancet HIV. 2025 Feb;12(2):e95-e104. Epub 2025 Jan 15. DOI: 10.1016/S2352-3018(24)00294-7. PMID: 39826566.
Link: Ver abstract / página de la revista

4. Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus dolutegravir as a two-drug regimen in adults naive to antiretroviral therapy (DYNAMIC): 24-week results from a randomised phase 2b study
Autores: Joshi SR, Masiá M, Mitha E, Castagna A, Cordova E, Ramgopal M, Gaudion A, Karthika S, Oyee J, Bainbridge V, Wynne B, Lataillade M.
Revista: EClinicalMedicine. 2025 Oct 17;89:103566. DOI: 10.1016/j.eclinm.2025.103566. PMID: 41357331.
Link: Ver abstract / página de la revista

5. Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus two NRTIs in adults naive to antiretroviral therapy (DOMINO): 24-week results from a randomised phase 2b study
Autores: Joshi SR, Cordova E, Mitha E, Castagna A, Ramgopal M, Llibre JM, Potthoff A, Chernova OE, Nuñez SA, Man C, Jeffrey JL, Fishman C, Oyee J, Joshi A, Zhang Y, Bainbridge V, Wynne B, Lataillade M.
Revista: EClinicalMedicine. 2025 Oct 17;89:103567. DOI: 10.1016/j.eclinm.2025.103567. PMID: 41357330.
Link: Ver abstract / página de la revista

6. Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study
Autores: Overton ET, Richmond G, Rizzardini G, Thalme A, Girard PM, Wong A, Porteiro N, Swindells S, Reynes J, Noe S, Harrington C, Español CM, Acuipil C, Aksar A, Wang Y, Ford SL, Crauwels H, van Eygen V, Van Solingen-Ristea R, Latham CL, Thiagarajah S, D’Amico R, Smith KY, Vandermeulen K, Spreen WR.
Revista: Clinical Infectious Diseases. 2023 May 3;76(9):1646-1654. DOI: 10.1093/cid/ciad020. PMID: 36660819.
Link: Ver abstract / página de la revista

7. Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment
Autores: Swindells S, Lutz T, Van Zyl L, Porteiro N, Stoll M, Mitha E, Shon A, Benn P, Huang JO, Harrington CM, Hove K, Ford SL, Talarico CL, Chounta V, Crauwels H, Van Solingen-Ristea R, Vanveggel S, Margolis DA, Smith KY, Vandermeulen K, Spreen WR.
Revista: AIDS. 2022 Feb 1;36(2):185-194. DOI: 10.1097/QAD.0000000000003025. PMID: 34261093.
Link: Ver abstract / página de la revista

8. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study
Autores: Orrell C, Hagins DP, Belonosova E, Porteiro N, Walmsley S, Falcó V, Man CY, Aylott A, Buchanan AM, Wynne B, Vavro C, Aboud M, Smith KY; ARIA study team.
Revista: The Lancet HIV. 2017 Dec;4(12):e536-e546. Epub 2017 Jul 17. DOI: 10.1016/S2352-3018(17)30095-4. PMID: 28729158.
Link: Ver abstract / página de la revista

9. Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study
Autores: Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Madero JS, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W, Wolff M, Gill J, Gatell J, Clarke A, Ruxrungtham K, Prazuck T, Kaiser R, Woolley I, Alberto Arnaiz J, Cooper D, Rockstroh JK, Mallon P, Emery S; MARCH study group.
Revista: HIV Medicine. 2018 Jan;19(1):65-71. Epub 2017 Jul 13. DOI: 10.1111/hiv.12532. PMID: 28703491.
Link: Ver abstract / página de la revista

10. Prevalencia de interacciones medicamentosas con fármacos anti-retrovirales en Buenos Aires, Argentina
Autores: Córdova E, Porteiro N, Loiza E, Mingrone H.
Revista: Revista Chilena de Infectología. 2016 Oct;33(Suppl 1):54-59. DOI: 10.4067/S0716-10182016000700006. PMID: 28453027.
Link: Ver abstract / página de la revista

11. Predicted susceptibility of etravirine in HIV patients experiencing virological failure secondary to non-nucleoside reverse transcriptase inhibitor resistance in Argentina
Autores: Córdova E, Loiza E, Porteiro N, Mingrone H.
Revista: Enfermedades Infecciosas y Microbiología Clínica. 2011 Jun-Jul;29(6):428-431. Epub 2011 May 17. DOI: 10.1016/j.eimc.2011.03.003. PMID: 21592625.
Link: Ver abstract / página de la revista